The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
COSTEM 2022 | The importance of bridging therapy in follicular and mantle cell lymphoma
Nicolaus Kröger, MD, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, briefly comments on the importance of bridging CAR-T therapy in relapsed/refractory (R/R) patients with mantle cell lymphoma (MCL) and follicular lymphoma (FL). This interview took place at the 7th Congress on Controversies in Stem Cell Transplantation and Cellular Therapies (COSTEM) in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
